Evidence map›Paper›PMID 39690272›Full record

ArticleOncogene2025

Identification of novel germline mutations in FUT7 and EXT1 linked with hereditary multiple exostoses.

Wan Peng, Gao-Fei Li, Guo-Wang Lin, Xi-Xi Cheng, Xiao-Yu Zuo, Qiao-Hong Lin, Shu-Qiang Liu, De-Jun Li, Dao-Chao Lin, Jun-Qiang Yin and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Wan Peng *Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, 510095, P. R. China.
Gao-Fei Li *Innovation Centre of Ministry of Education for Development and Diseases, School of medicine, South China University of Technology, Guangzhou, 510006, P. R. China.ORCID http://orcid.org/0000-0003-1155-6242
Guo-Wang LinState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060, P. R. China.
Xi-Xi ChengState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060, P. R. China.
Xiao-Yu ZuoState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060, P. R. China.
Qiao-Hong LinState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060, P. R. China.
Shu-Qiang LiuState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060, P. R. China.
De-Jun LiPrenatal Diagnosis Center, Reproductive Medicine Center, The First Hospital of Jilin University, Changchun, 130021, P. R. China.
Dao-Chao LinDepartment of Orthopaedics, Shulan (Hangzhou) Hospital, Hangzhou, 311000, P. R. China.
Jun-Qiang YinDepartment of Musculoskeletal Oncology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510080, P. R. China.ORCID http://orcid.org/0000-0001-8366-3480
Chun-Ling LuoState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060, P. R. China.ORCID http://orcid.org/0009-0005-1309-9673
Yi-Yue ZhangInnovation Centre of Ministry of Education for Development and Diseases, School of medicine, South China University of Technology, Guangzhou, 510006, P. R. China.ORCID http://orcid.org/0000-0002-9402-3523
Xian-Biao XieDepartment of Musculoskeletal Oncology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510080, P. R. China. xiexbiao@mail.sysu.edu.cn.ORCID http://orcid.org/0000-0003-3736-1291
Jin-Xin BeiAffiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, 510095, P. R. China. beijx@sysucc.org.cn.ORCID http://orcid.org/0000-0003-1333-407X

Funding

National Natural Science Foundation of China (National Science Foundation of China) 82130078 and 82261160657
6 · The paper itself

Abstract

Hereditary multiple exostoses (HME) is an autosomal dominant skeletal disorder primarily linked with mutations in Exostosin-1 (EXT1) and Exostosin-2 (EXT2) genes. However, not all HME cases can be explained by these mutations, and its pathogenic mechanisms are not fully understood. Herein, utilizing whole-exome sequencing and genetic screening with a family trio design, we identify two novel rare mutations co-segregating with HME in a Chinese family, including a nonsense mutation (c.204G>A, p.Trp68*) in EXT1 and a missense mutation (c.893T>G, p.Phe298Cys) in FUT7. Functional assays reveal that the FUT7 mutation affects the cellular localization of FUT7 protein and regulates cell proliferation. Notably, the simultaneous loss of fut7 and ext1 in a zebrafish model results in severe chondrodysplasia, indicating a functional link between FUT7 and EXT1 in chondrocyte regulation. Additionally, we unveil that FUT7 p.Phe298Cys reduces EXT1 expression through IL6/STAT3/SLUG axis at the transcription level and through ubiquitination-related proteasomal degradation at the protein level. Together, our findings not only identify novel germline mutations in FUT7 and EXT1 genes, but also highlight the critical interaction between these genes, suggesting a potential 'second-hit' mechanism over EXT1 mutations in HME pathogenesis. This insight enhances our understanding of the mechanisms underlying HME and opens new avenues for potential therapeutic interventions.

Indexed as

Exostoses, Multiple HereditaryFucosyltransferasesGerm-Line MutationN-AcetylglucosaminyltransferasesAnimalsExome SequencingExostosin 1FemaleGalactoside 2-alpha-L-fucosyltransferaseHumansMalePedigreeZebrafishExostosin 1FucosyltransferasesGalactoside 2-alpha-L-fucosyltransferaseN-Acetylglucosaminyltransferases

Identifiers

PMID39690272

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.